Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial. // The Lancet Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S1470204526003372?dgcid=rss_sd_all
Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet Oncology. https://www.sciencedirect.com/science/article/pii/S1470204526003372?dgcid=rss_sd_all
“Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial.” The Lancet Oncology.
@article{article68804,
title = {Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial},
journal = {The Lancet Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S1470204526003372?dgcid=rss_sd_all}
}